Chronos Archive seal

Review checklist: George H. W. Bush (HR-ML018)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the anticoagulation decision at CHA2DS2-VASc 1, the methimazole pretreatment, the levothyroxine starting dose, and the deviation recorded for the late sleep apnea screen.
provenance reviewnot_startedRecent-death rule: only White House statements in the Public Papers of the Presidents, a physician's newspaper account, a news report, and the White House biography are used. No political content; no relative's health is used.
safe messaging reviewnot_startedNo behavioral-health diagnosis; no sensitive claims; death recorded without detail.

Judgment calls (dossier editorial resolutions)

  1. Recent-death rule. He died in 2018. The case uses only what the White House and his physicians made public, as published in the Public Papers of the Presidents (the May 1991 statements and the March 1992 physical examination), a physician’s newspaper account, a news report, and the White House biography. No medical records, family accounts, or speculation about undisclosed conditions are used. The scores, laboratory values, doses, rhythm monitoring, anticoagulation, and preventive care are synthetic. The record is kept clinical: his office, work, and public life are not described beyond a generic synthetic occupation, and no political content is included. The recent-death review rule applies.
  2. Relatives. The White House statements of the time also discuss his spouse’s Graves’ disease and a review of possible shared environmental causes. Under the rule against attributing health facts to relatives, this is not used, no family history is recorded, and the spouse is unnamed and gives no history.
  3. Physicians named in the sources. The statements name the White House and hospital physicians. The claims say only “the White House said” and do not attribute decisions to named people.
  4. Index age. The modern episode presents him at 66, four days after the documented onset of atrial fibrillation and in the week Graves’ disease was diagnosed. The synthetic date of birth is June 12, 1959 (shift 35 years). The index visit on May 8, 2026 maps to May 8, 1991; the chronic-care visits on May 20, July 17, and September 11, 2026 map to the same days of 1991; and the annual wellness visit on October 16, 2026 maps to October 16, 1991, when he was 67. The modern hospital stay (May 4 to 6) mirrors the documented one, and the intake ECG in sinus rhythm agrees with the documented return to sinus rhythm. Past medical history includes only the documented episode of atrial fibrillation; the Graves’ diagnosis is made at the index visit.
  5. Treatment that differs from the historical record. The documented treatment of the arrhythmia was digoxin and procainamide. The modern episode uses current care instead: a beta-blocker for rate control, no antiarrhythmic, and a shared anticoagulation decision; the case does not claim he received metoprolol or apixaban. The historical treatment of Graves’ disease was radioactive iodine followed by lifelong thyroid hormone, which the case follows; methimazole pretreatment, the 15 mCi dose, the treatment date (May 29), and the levothyroxine doses (75 then 100 mcg) are synthetic. The exact date of his radioactive iodine treatment was not verified and is not asserted. The documented dose of 0.15 mg a day in March 1992 is later than the episode; the synthetic titration ends at 100 mcg with a TSH in range, which does not contradict it.
  6. Synthetic clinical picture. The fatigue at onset, the fast rate on arrival, the normal heart on ultrasound, the weight loss, and the later hypothyroidism are documented. Other symptoms (heat intolerance, a fine tremor, early hypothyroid symptoms), the diffuse goiter on examination, and all laboratory values are synthetic and were kept to what Graves’ disease and its treatment typically produce. No eye disease is recorded. His height (188 cm) and weights are synthetic. The tobacco and alcohol history (never tobacco; alcohol rarely) is synthetic; no fetched source covers it. CHA2DS2-VASc, HAS-BLED, STOP-BANG, the orbitopathy clinical activity score, and the Timed Up and Go have no verified LOINC code on the terminology server and are recorded as narrative.
  7. Annual wellness visit. A subsequent Medicare annual wellness visit (age 67, so `annual_wellness_subsequent`) was added on October 16, 2026 (true frame October 16, 1991), five weeks after the four-month review. He has been eligible for Medicare since 65, and the visit records an initial annual wellness visit with his previous clinician the year before, so the subsequent visit type applies. No sick visit was added: under the recent-death rule the case adds no synthetic illness episode. Judgment calls: (1) the TSH drawn at the wellness visit (2.6 mIU/L, five weeks after the dose increase) serves as the planned recheck; (2) colorectal screening is recorded as up to date without a result or interval, so that nothing reads as a claim about his real colonoscopy history; (3) he declines PSA testing after shared decision-making, a synthetic choice; (4) the eye examination is due, with Graves’ disease as an added reason; the documented raised eye pressure is later than the episode and is not used; (5) advance care planning names an unnamed agent and records only general priorities, with no treatment preference.
  8. Focused visits. The three chronic-care follow-ups (twelve days after intake, seven weeks after radioactive iodine, and four months after intake) are documented as focused visits on the CMID atrial fibrillation and hypothyroidism monographs, with the 2023 ACC/AHA/ACCP/HRS guideline and the ATA 2016 hyperthyroidism guideline for the thyrotoxic phase, and each lists every item those protocols call for at that point, with its interval and status. Protocol deviation recorded instead of an invented result: the sleep apnea screen due at the diagnosis of atrial fibrillation was missed at intake and at the twelve-day visit and was completed (negative) at the seven-week visit, with no harm and a corrective action. Apixaban was stopped at four months by shared decision after a 14-day ECG patch showed sinus rhythm throughout once he was no longer thyrotoxic (CHA2DS2-VASc 1, trigger treated); this is a judgment call for clinical review.
  9. Consultation. The endocrinology referral and the consultation by Anjali Kapoor, MD (a fictional consultant), on the day of the twelve-day visit, are S. The consultant answers the five referral questions with what the record shows happened afterwards: Graves’ disease confirmed without an uptake scan; radioactive iodine chosen over long-term methimazole or surgery and given nine days later; methimazole stopped three days before and not restarted; no orbitopathy and no steroid cover; hypothyroidism found at seven weeks and treated with levothyroxine started at 75 mcg and raised to 100 mcg; and the anticoagulation decision deferred until sinus rhythm was confirmed on ambulatory monitoring.
  10. Not used. His later health history (including the osteoarthritis and eye pressure reported in 1992, and illnesses in old age), the statements about his spouse, and his public office are not used in the episode. The 1992 physical examination is recorded as a claim only.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-05-20
Progress note 02 (C-CDA)
Sleep apnea symptom screenAt diagnosis and at least yearlyNot asked at intake or today. Deviation: the screen due at diagnosis was missed; it is added to the next visit's checklist

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-07-17
Progress note 03 (C-CDA)
ImagingAmbulatory rhythm monitoringOrdered14-day ECG patch in about five weeks, to confirm sinus rhythm before the anticoagulation decision
2026-10-16
Progress note 05 (C-CDA)
PreventionHepatitis C screeningOrderedOne-time screening recommended for adults 18 to 79; no result on record; drawn with his consent today

Evidence to check

Retrospective claims (R)

None.

Sensitive claims

None.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-05-08TSH0.005 mIU/L (low)Low
2026-05-08Free T43.6 ng/dL (high)High
2026-05-08Total T3280 ng/dL (high)High
2026-05-08TSH receptor antibody8.2 [IU]/L (high)High
2026-05-20TSH0.01 mIU/L (low)Low
2026-05-20Free T42.2 ng/dL (high)High
2026-07-17TSH5.6 mIU/L (high)High
2026-07-17Free T40.6 ng/dL (low)Low
2026-07-17Total T378 ng/dL (low)Low
2026-09-11TSH6.4 mIU/L (high)High